Contact a Recruiter
Updated on April 1, 2020
It’s hard to escape news about COVID-19. And with good reason. As an organisation on the front line of finding vaccines for diseases such as Coronavirus, our number one priority is the health and safety of our staff, our clinical trial participants, and the broader community.
We have answered some of the most frequently asked questions below. If you have any other questions, please get in touch with us at 651-641-2900.
Is there any impact from Coronavirus (COVID-19) on clinical trials at Nucleus Network sites (Centre for Clinical Studies, Q-Pharm or Prism)?
Nucleus Network is committed to continuing the vital work undertaken by our clinical trials, with studies continuing to take place.
While Coronavirus (COVID-19) infection rates in Melbourne, Brisbane and Minnesota remain low, the safety and quality of our trials and facilities is our number one priority. We have introduced strict measures to ensure the safety of all clinical trial participants, visitors and staff, and the quality of our trials.
In addition to the standard infection control practiced in its three clinics, Nucleus Network has implemented increased risk mitigations associated with Coronavirus (COVID-19). These include:
- Coronavirus (COVID-19) participant / patient screenings on phone and in-clinic,
- Regular hand sanitizing using alcohol-based hand rub with 70% alcohol,
- Every second bed practice to surpass ‘social distancing’ requirements,
- 6 feet spacing in waiting, dining and recreational areas,
- Personal Protective Equipment (PPE), are worn by medical officers, nursing and clinical staff during all participant interactions requiring close physical interaction.
- Isolation protocols are in place where additional PPE, including goggles, gowns and masks, are worn as appropriate when required for any person displaying high risk symptoms, this includes utilizing dedicated bed and bathroom bays
- Infection prevention and control procedures in line with World Health Organisation (WHO) and best practice guidelines.
These measures go above and beyond recommended clinical practices and provide a gold standard in infection control. We will continue to update and refine its approach to Coronavirus (COVID-19) as more information about the virus continues to be learned.
Can I still participate in a Nucleus Network clinical trial?
Yes. We are still recruiting for clinical trials however have implemented an age restriction on participants of 18-59 years (inclusive) to protect older members of our community. We are currently only allowing volunteers from the Minneapolis/St. Paul area.
The risk of Coronavirus (COVID-19) remains low for all our trial site locations (Melbourne, Brisbane and Minnesota), however, to protect the safety of our participants, staff and trial facilities, we have introduced some additional screening measures.
It is important that you self-isolate if you have knowingly contracted Coronavirus (COVID-19)
You must answer truthfully when providing information via our online, print and phone channels. Providing false information would equate to an offence.
Phone screening: Participants will be questioned over the phone to determine if they have any risk factors for Coronavirus (COVID-19) exposure.:
- Travel to or contact with someone who has travelled overseas or out of state within the last 14 days
- Have stayed or are currently residing in accommodation with high occupant turnover - This includes dormitory type accommodation within the last 14 days
- Had direct contact with anyone known to be infected with Coronavirus (COVID-19), and/or
- Currently have or have had cold / flu symptoms in the past 14 days.
Anyone who answers ‘yes’ to any of the questions above should not visit the unit. If you already have a screening appointment planned, please call 651-641-2900
Medical screening (in clinic): The above questions will again be asked when the participant presents for their screening visit and the participant will also have their temperature taken and be requested to wash their hands with hand sanitiser upon presentation. However, we ask that if participants do have any cold or flu like symptoms, they inform the clinic and do not attend their medical screening. We will advise the most appropriate action.
Outpatient visits (in clinic): Active trial participants attending the site for an inpatient or outpatient visit will be required to undergo the same process as described above. It is important for participant safety that all outpatient visits are attended as scheduled during the trial process. However, we ask that if participants do have any cold or flu like symptoms, they inform the clinic and not attend their medical screening. We will advise the most appropriate action.
Are clinical trials included under the ‘essential travel’ classification?
Yes. Clinical trials play an imperative, and essential, role in advancing medicines (including vaccines) for the entire community and therefore meet the essential travel requirements.
Have social distancing measures been implemented at Nucleus Network sites (Centre for Clinical Studies, Q-Pharm or Prism)?
Yes. Nucleus Network is strictly to social distancing measures with all Nucleus Network sites meeting the 6 ft per person distancing requirements. To ensure we meet, and surpass, this distance we have implemented an ‘every second bed’ policy, where the clinical beds are a minimum 6 feet apart.
What if I feel unwell after being admitted for a confinement period for a clinical trial?
Trial participants who begin to experience side effects, changes in their health or have concerns should always speak with the clinical staff / study doctor as soon as possible. In relation to Coronavirus (COVID-19), any fever, cough or other flu like symptoms noted should immediately be brought to the attention of clinical staff. We will need to medically assess participants and, if necessary, relocate to a different area for further treatment whilst it is established what the cause is.
Can I still have visitors during my stay at the facility?
Visitors are usually permitted during long-stay trial admissions. However, to reduce risk of Coronavirus (COVID-19) transmission we will be restricting visitor access at our facilities until further notice. We apologise for this inconvenience and understand the stress this may cause in some cases. We will work with trial participants to find alternative ways to remain in contact with family and friends.
With your help, we can make a difference in the containment of COVID-19 as together we work on developing the medicines of tomorrow.
Registration form here.
Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies.
If you have registered with Prism in the past, please call Dayna 651-724-5047 to update your profile or learn about available studies.
Find the registration form here.
Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call Geoff at 651-641-2911 with questions.
We will not share or sell this info with any third party.
Thanks for your interest!** Due to COVID-19, we are not accepting volunteers from outside the local Minneapolis/St. Paul area into any studies. Stay tuned for updates. We appreciate your patience!**
BMI stands for "Body Mass Index," and it's a calculation determined by your height and weight. There is almost always a BMI range in Prism's studies.
Why does the BMI range exist? To provide an expected norm within which the population of participants will fall.
Why is there a BMI limit? A participant with a higher BMI may require a greater dose of the study drug and therefore may metabolize the drug differently than a person with a lower BMI.
Why does the BMI range change from study to study? The range is determined by the study sponsor. The range is based on the type of study, the procedures being done, and the study drug.
Determine your BMI here
Prism is excited to announce we have started PRISM TEXT! This texting feature will be a convenient way for the Recruitment Department to TEXT you about upcoming studies.
You will be receiving text message from us if you are qualified for a study.
You are considered OPT-IN unless you tell us to remove you (OPT OUT).
The texting system is through our secure online database and will not compromise your phone number.
Please let us know if you have any questions!
Prism has a variety of upcoming studies to participate in:
- Inpatient and Outpatient studies for healthy males and females; Age 18-55 years old
- Liver Impairment
- Kidney Impairment
To be put on the call list and receive more information, when available, please contact Dayna at email@example.com or Lindsay at firstname.lastname@example.org.
Schedule a time to talk: https://calendly.com/daynas/liverimpairmentinterest
Prism Research has upcoming studies for individuals diagnosed with liver impairment. These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.
If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.
Please contact Dayna at 651-724-5047 or email@example.com
Schedule a time to talk: https://bit.ly/2UBaoAE
Prism Research has upcoming studies for individuals diagnosed with kidney impairment. These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of kidney impairment when compared to volunteers with normal kidney function.
If you or someone you know has been diagnosed with kidney impairment and are interested in being considered for these studies, please contact Lindsay at 651-368-3360 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.
Please contact Lindsay at 651-368-3360 or firstname.lastname@example.org
Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.
It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!
- Subject must qualify for a study.
- Subject may not be referred more than one time.
- Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any prior study at Prism.
- In the event that a subject is referred by multiple people, the first person who referred will receive payment.
- Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.
HEALTHY: CLINICAL RESEARCH STUDY 2003
- To evaluate how nutritional components, alter caffeine absorption/metabolism after drinking a caffeinated beverage
GENERAL STUDY REQUIREMENTS:
- Men between the ages 18-55 years old
- Must be healthy and not taking any medications
- Must have a BMI of 18.0-29.0
- Must be a Non-smoker
- Clinic Visits: 1 Screening and 4 follow up visits
- Screening may last up to 3.5 consecutive hours
- Visits may last 5-6 consecutive hour
METHOD OF ADMINISTRATION:
- Compensation for study participation may be provided for time and travel up to $700.00
- Dayna 651-724-5047 or email@example.com
Schedule a phone pre-screen: https://bit.ly/2LrC5Yx
HEALTHY MALES: CLINICAL RESEARCH STUDY 2008
- To evaluate the effects of FDA approved gemfibrozil or rifampicin on SAR442168. SAR442168 is being developed to treat relapsing and progressive forms of MS.
GENERAL STUDY REQUIREMENTS:
- Men between the ages 18-45 years old
- Must be healthy and not taking any medications
- Weight between 110-220 lbs and have a BMI of 18-30.0
- Non-smokers or occasional smokers and able to stop for duration of study
- Clinic Visits: 1 Screening and 1 follow up phone call
- In clinic stay
- Cohort 1: 8 nights/9 days
- Cohort 2: 10 nights/11 days
- Total Study Duration: up to 46 days
METHOD OF ADMINISTRATION:
- Oral pills
- Compensation for study participation may be provided for time and travel.
- Cohort 1: Total compensation up to $2,050
- Cohort 2: Total compensation up to $2,550
- Lindsay 651-368-3360 or firstname.lastname@example.org
Have you LIKED Prism Clinical Research on Facebook?
Have you TAGGED Prism Clinical Research on Twitter?
Have you FOLLOWED Prism Clinical Research on Instagram?
Have you SEARCHED 651-368-3360 on Whatsapp?
Have you WRITTEN A REVIEW on Google?
Have you WATCHED on YouTube?
Use the links below:↓
If you are interested in details about this study, please contact
Dayna at 651-724-5047 or email@example.com